APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Neuromyelitis Optica Therapy

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Neuromyelitis Optica Therapy Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

Report ID 17401662032 January 2026192 pages

Choose your research edition.

Industry ResearchNeuromyelitis Optica Therapy Industry Research Report 2026117 pages · $2,950 USDIndustry Growth & TrendsGlobal Neuromyelitis Optica Therapy Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal Neuromyelitis Optica Therapy Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Neuromyelitis Optica Therapy Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Neuromyelitis Optica Therapy Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Neuromyelitis Optica Therapy market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The US & Canada market for Neuromyelitis Optica Therapy is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Neuromyelitis Optica Therapy is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Neuromyelitis Optica Therapy is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Neuromyelitis Optica Therapy is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Neuromyelitis Optica Therapy include CBOP, CSL, Fresenius, Grifols, Gyjtrs, Intas, NANG KUANG, Octapharma and Tianjin Kingyork, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Includes

This report provides an overview of the global Neuromyelitis Optica Therapy market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Neuromyelitis Optica Therapy and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Neuromyelitis Optica Therapy revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the Neuromyelitis Optica Therapy market size, projected growth trends, production technologies, key applications, and end-use industries.

Neuromyelitis Optica Therapy Segment by Company

CBOP

CSL

Fresenius

Grifols

Gyjtrs

Intas

NANG KUANG

Octapharma

Tianjin Kingyork

Baxter

Pfizer

Sandoz

Teva

Neuromyelitis Optica Therapy Segment by Type

Glucocorticoids

Immunotherapies

Other

Neuromyelitis Optica Therapy Segment by Application

Acute Attack

Remission Prophylactic Treatment

Neuromyelitis Optica Therapy Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Neuromyelitis Optica Therapy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Neuromyelitis Optica Therapy and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Neuromyelitis Optica Therapy.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Neuromyelitis Optica Therapy in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Neuromyelitis Optica Therapy industry.

Chapter 3: Detailed analysis of Neuromyelitis Optica Therapy companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Neuromyelitis Optica Therapyrevenue, gross margin, and recent development, etc.

Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.

Chapter 8: Europe by type, by application and by country, revenue for each segment.

Chapter 9: China by type, and by application, revenue for each segment.

Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.

Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.

Chapter 12: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Neuromyelitis Optica Therapy Market Size Growth Rate by Type (US$ Million): 2021 VS 2025 VS 2032 Table 2. Key Players of Glucocorticoids Table 3. Key Players of Immunotherapies Table 4. Key Players of Other Table 4. Global Neuromyelitis Optica Therapy Market Size Growth Rate by Application (US$ Million): 2021 VS 2025 VS 2032 Table 5. Key Players of Acute Attack Table 6. Key Players of Remission Prophylactic Treatment Table 7. Global Neuromyelitis Optica Therapy Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 8. Global Neuromyelitis Optica Therapy Market Size by Region (2021-2026) & (US$ Million) Table 9. Global Neuromyelitis Optica Therapy Market Share by Region (2021-2026) Table 10. Global Neuromyelitis Optica Therapy Market Size by Region (2027-2032) & (US$ Million) Table 11. Global Neuromyelitis Optica Therapy Market Share by Region (2027-2032) Table 12. Neuromyelitis Optica Therapy Industry Trends Table 13. Neuromyelitis Optica Therapy Industry Drivers Table 14. Neuromyelitis Optica Therapy Industry Opportunities and Challenges Table 15. Neuromyelitis Optica Therapy Industry Restraints Table 16. Global Neuromyelitis Optica Therapy Revenue by Company (US$ Million) & (2021-2026) Table 17. Global Neuromyelitis Optica Therapy Revenue Market Share by Company (2021-2026) Table 18. Global Neuromyelitis Optica Therapy Players Revenue Ranking, 2024 VS 2025 VS 2026 Table 19. Global Neuromyelitis Optica Therapy Key Company Head Office and Area Served Table 20. Global Neuromyelitis Optica Therapy Company, Product Type & Application Table 21. Global Neuromyelitis Optica Therapy Company Establishment Date Table 22. Global Company Market Concentration Ratio (CR5 and HHI) Table 23. Global Neuromyelitis Optica Therapy by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 24. Global Neuromyelitis Optica Therapy Market Size by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Neuromyelitis Optica Therapy Market Size by Type (2021-2026) & (US$ Million) Table 26. Global Neuromyelitis Optica Therapy Market Size by Type (2027-2032) & (US$ Million) Table 27. Global Neuromyelitis Optica Therapy Revenue Market Share by Type (2021-2026) Table 28. Global Neuromyelitis Optica Therapy Revenue Market Share by Type (2027-2032) Table 29. Global Neuromyelitis Optica Therapy Market Size by Application 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Neuromyelitis Optica Therapy Market Size by Application (2021-2026) & (US$ Million) Table 31. Global Neuromyelitis Optica Therapy Market Size by Application (2027-2032) & (US$ Million) Table 32. Global Neuromyelitis Optica Therapy Revenue Market Share by Application (2021-2026) Table 33. Global Neuromyelitis Optica Therapy Revenue Market Share by Application (2027-2032) Table 34. CBOP Company Information Table 35. CBOP Business Overview Table 36. CBOP Neuromyelitis Optica Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 37. CBOP Neuromyelitis Optica Therapy Product Portfolio Table 38. CBOP Recent Development Table 39. CSL Company Information Table 40. CSL Business Overview Table 41. CSL Neuromyelitis Optica Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 42. CSL Neuromyelitis Optica Therapy Product Portfolio Table 43. CSL Recent Development Table 44. Fresenius Company Information Table 45. Fresenius Business Overview Table 46. Fresenius Neuromyelitis Optica Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 47. Fresenius Neuromyelitis Optica Therapy Product Portfolio Table 48. Fresenius Recent Development Table 49. Grifols Company Information Table 50. Grifols Business Overview Table 51. Grifols Neuromyelitis Optica Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 52. Grifols Neuromyelitis Optica Therapy Product Portfolio Table 53. Grifols Recent Development Table 54. Gyjtrs Company Information Table 55. Gyjtrs Business Overview Table 56. Gyjtrs Neuromyelitis Optica Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 57. Gyjtrs Neuromyelitis Optica Therapy Product Portfolio Table 58. Gyjtrs Recent Development Table 59. Intas Company Information Table 60. Intas Business Overview Table 61. Intas Neuromyelitis Optica Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 62. Intas Neuromyelitis Optica Therapy Product Portfolio Table 63. Intas Recent Development Table 64. NANG KUANG Company Information Table 65. NANG KUANG Business Overview Table 66. NANG KUANG Neuromyelitis Optica Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 67. NANG KUANG Neuromyelitis Optica Therapy Product Portfolio Table 68. NANG KUANG Recent Development Table 69. Octapharma Company Information Table 70. Octapharma Business Overview Table 71. Octapharma Neuromyelitis Optica Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 72. Octapharma Neuromyelitis Optica Therapy Product Portfolio Table 73. Octapharma Recent Development Table 74. Tianjin Kingyork Company Information Table 75. Tianjin Kingyork Business Overview Table 76. Tianjin Kingyork Neuromyelitis Optica Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 77. Tianjin Kingyork Neuromyelitis Optica Therapy Product Portfolio Table 78. Tianjin Kingyork Recent Development Table 79. Baxter Company Information Table 80. Baxter Business Overview Table 81. Baxter Neuromyelitis Optica Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 82. Baxter Neuromyelitis Optica Therapy Product Portfolio Table 83. Baxter Recent Development Table 84. Pfizer Company Information Table 85. Pfizer Business Overview Table 86. Pfizer Neuromyelitis Optica Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 87. Pfizer Neuromyelitis Optica Therapy Product Portfolio Table 88. Pfizer Recent Development Table 89. Sandoz Company Information Table 90. Sandoz Business Overview Table 91. Sandoz Neuromyelitis Optica Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 92. Sandoz Neuromyelitis Optica Therapy Product Portfolio Table 93. Sandoz Recent Development Table 94. Teva Company Information Table 95. Teva Business Overview Table 96. Teva Neuromyelitis Optica Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 97. Teva Neuromyelitis Optica Therapy Product Portfolio Table 98. Teva Recent Development Table 99. North America Neuromyelitis Optica Therapy Market Size by Type (2021-2026) & (US$ Million) Table 100. North America Neuromyelitis Optica Therapy Market Size by Type (2027-2032) & (US$ Million) Table 101. North America Neuromyelitis Optica Therapy Market Size by Application (2021-2026) & (US$ Million) Table 102. North America Neuromyelitis Optica Therapy Market Size by Application (2027-2032) & (US$ Million) Table 103. North America Neuromyelitis Optica Therapy Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 104. North America Neuromyelitis Optica Therapy Market Size by Country (2021-2026) Table 105. North America Neuromyelitis Optica Therapy Market Size by Country (2027-2032) Table 106. Europe Neuromyelitis Optica Therapy Market Size by Type (2021-2026) & (US$ Million) Table 107. Europe Neuromyelitis Optica Therapy Market Size by Type (2027-2032) & (US$ Million) Table 108. Europe Neuromyelitis Optica Therapy Market Size by Application (2021-2026) & (US$ Million) Table 109. Europe Neuromyelitis Optica Therapy Market Size by Application (2027-2032) & (US$ Million) Table 110. Europe Neuromyelitis Optica Therapy Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 111. Europe Neuromyelitis Optica Therapy Market Size by Country (2021-2026) Table 112. Europe Neuromyelitis Optica Therapy Market Size by Country (2027-2032) Table 113. China Neuromyelitis Optica Therapy Market Size by Type (2021-2026) & (US$ Million) Table 114. China Neuromyelitis Optica Therapy Market Size by Type (2027-2032) & (US$ Million) Table 115. China Neuromyelitis Optica Therapy Market Size by Application (2021-2026) & (US$ Million) Table 116. China Neuromyelitis Optica Therapy Market Size by Application (2027-2032) & (US$ Million) Table 117. Asia Neuromyelitis Optica Therapy Market Size by Type (2021-2026) & (US$ Million) Table 118. Asia Neuromyelitis Optica Therapy Market Size by Type (2027-2032) & (US$ Million) Table 119. Asia Neuromyelitis Optica Therapy Market Size by Application (2021-2026) & (US$ Million) Table 120. Asia Neuromyelitis Optica Therapy Market Size by Application (2027-2032) & (US$ Million) Table 121. Asia Neuromyelitis Optica Therapy Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 122. Asia Neuromyelitis Optica Therapy Market Size by Country (2021-2026) Table 123. Asia Neuromyelitis Optica Therapy Market Size by Country (2027-2032) Table 124. South America, Middle East & Africa Neuromyelitis Optica Therapy Market Size by Type (2021-2026) & (US$ Million) Table 125. South America, Middle East & Africa Neuromyelitis Optica Therapy Market Size by Type (2027-2032) & (US$ Million) Table 126. South America, Middle East & Africa Neuromyelitis Optica Therapy Market Size by Application (2021-2026) & (US$ Million) Table 127. South America, Middle East & Africa Neuromyelitis Optica Therapy Market Size by Application (2027-2032) & (US$ Million) Table 128. South America, Middle East & Africa Neuromyelitis Optica Therapy Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 129. South America, Middle East & Africa Neuromyelitis Optica Therapy Market Size by Country (2021-2026) Table 130. South America, Middle East & Africa Neuromyelitis Optica Therapy Market Size by Country (2027-2032) Table 131. Research Programs/Design for This Report Table 132. Authors List of This Report Table 133. Secondary Sources Table 134. Primary Sources List of Figures Figure 1. Neuromyelitis Optica Therapy Product Image Figure 2. Global Neuromyelitis Optica Therapy Market Size Growth Rate by Type, 2021 VS 2025 VS 2032 (US$ Million) Figure 3. Global Neuromyelitis Optica Therapy Market Share by Type: 2025 VS 2032 Figure 4. Glucocorticoids Image Figure 5. Immunotherapies Image Figure 6. Other Image Figure 7. Global Neuromyelitis Optica Therapy Market Size Growth Rate by Application, 2021 VS 2025 VS 2032 (US$ Million) Figure 8. Global Neuromyelitis Optica Therapy Market Share by Application: 2025 VS 2032 Figure 9. Acute Attack Image Figure 10. Remission Prophylactic Treatment Image Figure 11. Global Neuromyelitis Optica Therapy Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 12. Global Neuromyelitis Optica Therapy Market Size (2021-2032) & (US$ Million) Figure 13. Global Neuromyelitis Optica Therapy Market Share by Region: 2025 VS 2032 Figure 14. Years Considered Figure 15. Global Neuromyelitis Optica Therapy Market Share by Players in 2025 Figure 16. Global Top 5 and 10 Neuromyelitis Optica Therapy Players Market Share by Revenue in 2025 Figure 17. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 18. Global Neuromyelitis Optica Therapy Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Neuromyelitis Optica Therapy Revenue Market Share by Type (2021-2032) Figure 20. Global Neuromyelitis Optica Therapy Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Neuromyelitis Optica Therapy Revenue Market Share by Application (2021-2032) Figure 22. North America Neuromyelitis Optica Therapy Market Size (2021-2032) & (US$ Million) Figure 23. North America Neuromyelitis Optica Therapy Market Share by Type (2021-2032) Figure 24. North America Neuromyelitis Optica Therapy Market Share by Application (2021-2032) Figure 25. North America Neuromyelitis Optica Therapy Market Share by Country (2021-2032) Figure 26. United States Neuromyelitis Optica Therapy Market Size (2021-2032) & (US$ Million) Figure 27. Canada Neuromyelitis Optica Therapy Market Size (2021-2032) & (US$ Million) Figure 28. Mexico Neuromyelitis Optica Therapy Market Size (2021-2032) & (US$ Million) Figure 29. Europe Neuromyelitis Optica Therapy Market Size (2021-2032) & (US$ Million) Figure 30. Europe Neuromyelitis Optica Therapy Market Share by Type (2021-2032) Figure 31. Europe Neuromyelitis Optica Therapy Market Share by Application (2021-2032) Figure 32. Europe Neuromyelitis Optica Therapy Market Share by Country (2021-2032) Figure 33. Germany Neuromyelitis Optica Therapy Market Size (2021-2032) & (US$ Million) Figure 34. France Neuromyelitis Optica Therapy Market Size (2021-2032) & (US$ Million) Figure 35. U.K. Neuromyelitis Optica Therapy Market Size (2021-2032) & (US$ Million) Figure 36. Italy Neuromyelitis Optica Therapy Market Size (2021-2032) & (US$ Million) Figure 37. Russia Neuromyelitis Optica Therapy Market Size (2021-2032) & (US$ Million) Figure 38. Nordic Countries Neuromyelitis Optica Therapy Market Size (2021-2032) & (US$ Million) Figure 39. China Neuromyelitis Optica Therapy Market Size (2021-2032) & (US$ Million) Figure 40. China Neuromyelitis Optica Therapy Market Share by Type (2021-2032) Figure 41. China Neuromyelitis Optica Therapy Market Share by Application (2021-2032) Figure 42. Asia Neuromyelitis Optica Therapy Market Size (2021-2032) & (US$ Million) Figure 43. Asia Neuromyelitis Optica Therapy Market Share by Type (2021-2032) Figure 44. Asia Neuromyelitis Optica Therapy Market Share by Application (2021-2032) Figure 45. Asia Neuromyelitis Optica Therapy Market Share by Country (2021-2032) Figure 46. Japan Neuromyelitis Optica Therapy Market Size (2021-2032) & (US$ Million) Figure 47. South Korea Neuromyelitis Optica Therapy Market Size (2021-2032) & (US$ Million) Figure 48. Taiwan Neuromyelitis Optica Therapy Market Size (2021-2032) & (US$ Million) Figure 49. Southeast Asia Neuromyelitis Optica Therapy Market Size (2021-2032) & (US$ Million) Figure 50. India Neuromyelitis Optica Therapy Market Size (2021-2032) & (US$ Million) Figure 51. Australia Neuromyelitis Optica Therapy Market Size (2021-2032) & (US$ Million) Figure 52. South America, Middle East & Africa Neuromyelitis Optica Therapy Market Size (2021-2032) & (US$ Million) Figure 53. South America, Middle East & Africa Neuromyelitis Optica Therapy Market Share by Type (2021-2032) Figure 54. South America, Middle East & Africa Neuromyelitis Optica Therapy Market Share by Application (2021-2032) Figure 55. South America, Middle East & Africa Neuromyelitis Optica Therapy Market Share by Country (2021-2032) Figure 56. Brazil Neuromyelitis Optica Therapy Market Size (2021-2032) & (US$ Million) Figure 57. South Africa Neuromyelitis Optica Therapy Market Size (2021-2032) & (US$ Million) Figure 58. Saudi Arabia Neuromyelitis Optica Therapy Market Size (2021-2032) & (US$ Million) Figure 59. Turkey Neuromyelitis Optica Therapy Market Size (2021-2032) & (US$ Million) Figure 60. Argentina Neuromyelitis Optica Therapy Market Size (2021-2032) & (US$ Million) Figure 61. UAE Neuromyelitis Optica Therapy Market Size (2021-2032) & (US$ Million) Figure 62. Egypt Neuromyelitis Optica Therapy Market Size (2021-2032) & (US$ Million) Figure 63. Chile Neuromyelitis Optica Therapy Market Size (2021-2032) & (US$ Million) Figure 64. Research Process Figure 65. Key Executives Interviewed

Scope & coverage.

Types
  • Glucocorticoids
  • Immunotherapies
  • Other
Applications
  • Acute Attack
  • Remission Prophylactic Treatment
Companies covered
  • CBOP
  • CSL
  • Fresenius
  • Grifols
  • Gyjtrs
  • Intas
  • NANG KUANG
  • Octapharma
  • Tianjin Kingyork
  • Baxter
  • Pfizer
  • Sandoz
  • Teva

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Market Analysis by Type
  3. 1.2.1 Global Neuromyelitis Optica Therapy Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
  4. 1.2.2 Glucocorticoids
  5. 1.2.3 Immunotherapies
  6. 1.2.4 Other
  7. 1.3 Market Analysis by Application
  8. 1.3.1 Global Neuromyelitis Optica Therapy Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
  9. 1.3.2 Acute Attack
  10. 1.3.3 Remission Prophylactic Treatment
  11. 1.4 Global Market Growth Prospects
  12. 1.5 Global Neuromyelitis Optica Therapy Growth Trends by Region
  13. 1.5.1 Global Neuromyelitis Optica Therapy Market Size by Region: 2021 VS 2025 VS 2032
  14. 1.5.2 Neuromyelitis Optica Therapy Market Size by Region (2021-2026)
  15. 1.5.3 Neuromyelitis Optica Therapy Market Size by Region (2027-2032)
  16. 1.6 Assumptions and Limitations
  17. 1.7 Study Goals and Objectives
  18. 1.8 Years Considered
2 Global Neuromyelitis Optica Therapy Market Dynamics
  1. 2.1 Neuromyelitis Optica Therapy Industry Trends
  2. 2.2 Neuromyelitis Optica Therapy Industry Drivers
  3. 2.3 Neuromyelitis Optica Therapy Industry Opportunities and Challenges
  4. 2.4 Neuromyelitis Optica Therapy Industry Restraints
3 Competitive Landscape by Company
  1. 3.1 Global Neuromyelitis Optica Therapy Revenue by Company (2021-2026)
  2. 3.2 Global Neuromyelitis Optica Therapy Players Revenue Ranking, 2024 VS 2025 VS 2026
  3. 3.3 Global Neuromyelitis Optica Therapy Key Company Head office and Area Served
  4. 3.4 Global Neuromyelitis Optica Therapy Company, Product Type & Application
  5. 3.5 Global Neuromyelitis Optica Therapy Company Establishment Date
  6. 3.6 Market Competitive Analysis
  7. 3.6.1 Global Neuromyelitis Optica Therapy Market CR5 and HHI
  8. 3.6.2 Global Top 5 and 10 Neuromyelitis Optica Therapy Players Market Share by Revenue in 2025
  9. 3.6.3 2025 Neuromyelitis Optica Therapy Tier 1, Tier 2, and Tier 3
4 Neuromyelitis Optica Therapy Market by Type
  1. 4.1 Global Neuromyelitis Optica Therapy Market Size by Type (2021 VS 2025 VS 2032)
  2. 4.2 Global Neuromyelitis Optica Therapy Market Size by Type (2021-2032)
  3. 4.3 Global Neuromyelitis Optica Therapy Market Size Share by Type (2021-2032)
5 Neuromyelitis Optica Therapy Market by Application
  1. 5.1 Global Neuromyelitis Optica Therapy Market Size by Application (2021 VS 2025 VS 2032)
  2. 5.2 Global Neuromyelitis Optica Therapy Market Size by Application (2021-2032)
  3. 5.3 Global Neuromyelitis Optica Therapy Market Size Share by Application (2021-2032)
6 Company Profiles
  1. 6.1 CBOP
  2. 6.1.1 CBOP Company Information
  3. 6.1.2 CBOP Business Overview
  4. 6.1.3 CBOP Neuromyelitis Optica Therapy Revenue and Gross Margin (US$ Million) & (2021-2026)
  5. 6.1.4 CBOP Neuromyelitis Optica Therapy Product Portfolio
  6. 6.1.5 CBOP Recent Developments
  7. 6.2 CSL
  8. 6.2.1 CSL Company Information
  9. 6.2.2 CSL Business Overview
  10. 6.2.3 CSL Neuromyelitis Optica Therapy Revenue and Gross Margin (US$ Million) & (2021-2026)
  11. 6.2.4 CSL Neuromyelitis Optica Therapy Product Portfolio
  12. 6.2.5 CSL Recent Developments
  13. 6.3 Fresenius
  14. 6.3.1 Fresenius Company Information
  15. 6.3.2 Fresenius Business Overview
  16. 6.3.3 Fresenius Neuromyelitis Optica Therapy Revenue and Gross Margin (US$ Million) & (2021-2026)
  17. 6.3.4 Fresenius Neuromyelitis Optica Therapy Product Portfolio
  18. 6.3.5 Fresenius Recent Developments
  19. 6.4 Grifols
  20. 6.4.1 Grifols Company Information
  21. 6.4.2 Grifols Business Overview
  22. 6.4.3 Grifols Neuromyelitis Optica Therapy Revenue and Gross Margin (US$ Million) & (2021-2026)
  23. 6.4.4 Grifols Neuromyelitis Optica Therapy Product Portfolio
  24. 6.4.5 Grifols Recent Developments
  25. 6.5 Gyjtrs
  26. 6.5.1 Gyjtrs Company Information
  27. 6.5.2 Gyjtrs Business Overview
  28. 6.5.3 Gyjtrs Neuromyelitis Optica Therapy Revenue and Gross Margin (US$ Million) & (2021-2026)
  29. 6.5.4 Gyjtrs Neuromyelitis Optica Therapy Product Portfolio
  30. 6.5.5 Gyjtrs Recent Developments
  31. 6.6 Intas
  32. 6.6.1 Intas Company Information
  33. 6.6.2 Intas Business Overview
  34. 6.6.3 Intas Neuromyelitis Optica Therapy Revenue and Gross Margin (US$ Million) & (2021-2026)
  35. 6.6.4 Intas Neuromyelitis Optica Therapy Product Portfolio
  36. 6.6.5 Intas Recent Developments
  37. 6.7 NANG KUANG
  38. 6.7.1 NANG KUANG Company Information
  39. 6.7.2 NANG KUANG Business Overview
  40. 6.7.3 NANG KUANG Neuromyelitis Optica Therapy Revenue and Gross Margin (US$ Million) & (2021-2026)
  41. 6.7.4 NANG KUANG Neuromyelitis Optica Therapy Product Portfolio
  42. 6.7.5 NANG KUANG Recent Developments
  43. 6.8 Octapharma
  44. 6.8.1 Octapharma Company Information
  45. 6.8.2 Octapharma Business Overview
  46. 6.8.3 Octapharma Neuromyelitis Optica Therapy Revenue and Gross Margin (US$ Million) & (2021-2026)
  47. 6.8.4 Octapharma Neuromyelitis Optica Therapy Product Portfolio
  48. 6.8.5 Octapharma Recent Developments
  49. 6.9 Tianjin Kingyork
  50. 6.9.1 Tianjin Kingyork Company Information
  51. 6.9.2 Tianjin Kingyork Business Overview
  52. 6.9.3 Tianjin Kingyork Neuromyelitis Optica Therapy Revenue and Gross Margin (US$ Million) & (2021-2026)
  53. 6.9.4 Tianjin Kingyork Neuromyelitis Optica Therapy Product Portfolio
  54. 6.9.5 Tianjin Kingyork Recent Developments
  55. 6.10 Baxter
  56. 6.10.1 Baxter Company Information
  57. 6.10.2 Baxter Business Overview
  58. 6.10.3 Baxter Neuromyelitis Optica Therapy Revenue and Gross Margin (US$ Million) & (2021-2026)
  59. 6.10.4 Baxter Neuromyelitis Optica Therapy Product Portfolio
  60. 6.10.5 Baxter Recent Developments
  61. 6.11 Pfizer
  62. 6.11.1 Pfizer Company Information
  63. 6.11.2 Pfizer Business Overview
  64. 6.11.3 Pfizer Neuromyelitis Optica Therapy Revenue and Gross Margin (US$ Million) & (2021-2026)
  65. 6.11.4 Pfizer Neuromyelitis Optica Therapy Product Portfolio
  66. 6.11.5 Pfizer Recent Developments
  67. 6.12 Sandoz
  68. 6.12.1 Sandoz Company Information
  69. 6.12.2 Sandoz Business Overview
  70. 6.12.3 Sandoz Neuromyelitis Optica Therapy Revenue and Gross Margin (US$ Million) & (2021-2026)
  71. 6.12.4 Sandoz Neuromyelitis Optica Therapy Product Portfolio
  72. 6.12.5 Sandoz Recent Developments
  73. 6.13 Teva
  74. 6.13.1 Teva Company Information
  75. 6.13.2 Teva Business Overview
  76. 6.13.3 Teva Neuromyelitis Optica Therapy Revenue and Gross Margin (US$ Million) & (2021-2026)
  77. 6.13.4 Teva Neuromyelitis Optica Therapy Product Portfolio
  78. 6.13.5 Teva Recent Developments
7 North America
  1. 7.1 North America Neuromyelitis Optica Therapy Market Size (2021-2032)
  2. 7.2 North America Neuromyelitis Optica Therapy Market Size by Type
  3. 7.2.1 North America Neuromyelitis Optica Therapy Market Size by Type (2021-2026)
  4. 7.2.2 North America Neuromyelitis Optica Therapy Market Size by Type (2027-2032)
  5. 7.2.3 North America Neuromyelitis Optica Therapy Market Share by Type (2021-2032)
  6. 7.3 North America Neuromyelitis Optica Therapy Market Size by Application
  7. 7.3.1 North America Neuromyelitis Optica Therapy Market Size by Application (2021-2026)
  8. 7.3.2 North America Neuromyelitis Optica Therapy Market Size by Application (2027-2032)
  9. 7.3.3 North America Neuromyelitis Optica Therapy Market Share by Application (2021-2032)
  10. 7.4 North America Neuromyelitis Optica Therapy Market Size by Country
  11. 7.4.1 North America Neuromyelitis Optica Therapy Market Size by Country (2021 VS 2025 VS 2032)
  12. 7.4.2 North America Neuromyelitis Optica Therapy Market Size by Country (2021-2026)
  13. 7.4.3 North America Neuromyelitis Optica Therapy Market Size by Country (2027-2032)
  14. 7.4.4 North America Neuromyelitis Optica Therapy Market Share by Country (2021-2032)
  15. 7.4.5 United States
  16. 7.4.6 Canada
  17. 7.4.7 Mexico
8 Europe
  1. 8.1 Europe Neuromyelitis Optica Therapy Market Size (2021-2032)
  2. 8.2 Europe Neuromyelitis Optica Therapy Market Size by Type
  3. 8.2.1 Europe Neuromyelitis Optica Therapy Market Size by Type (2021-2026)
  4. 8.2.2 Europe Neuromyelitis Optica Therapy Market Size by Type (2027-2032)
  5. 8.2.3 Europe Neuromyelitis Optica Therapy Market Share by Type (2021-2032)
  6. 8.3 Europe Neuromyelitis Optica Therapy Market Size by Application
  7. 8.3.1 Europe Neuromyelitis Optica Therapy Market Size by Application (2021-2026)
  8. 8.3.2 Europe Neuromyelitis Optica Therapy Market Size by Application (2027-2032)
  9. 8.3.3 Europe Neuromyelitis Optica Therapy Market Share by Application (2021-2032)
  10. 8.4 Europe Neuromyelitis Optica Therapy Market Size by Country
  11. 8.4.1 Europe Neuromyelitis Optica Therapy Market Size by Country (2021 VS 2025 VS 2032)
  12. 8.4.2 Europe Neuromyelitis Optica Therapy Market Size by Country (2021-2026)
  13. 8.4.3 Europe Neuromyelitis Optica Therapy Market Size by Country (2027-2032)
  14. 8.4.4 Europe Neuromyelitis Optica Therapy Market Share by Country (2021-2032)
  15. 8.4.5 Germany
  16. 8.4.6 France
  17. 8.4.7 U.K.
  18. 8.4.8 Italy
  19. 8.4.9 Russia
  20. 8.4.10 Nordic Countries
9 China
  1. 9.1 China Neuromyelitis Optica Therapy Market Size (2021-2032)
  2. 9.2 China Neuromyelitis Optica Therapy Market Size by Type
  3. 9.2.1 China Neuromyelitis Optica Therapy Market Size by Type (2021-2026)
  4. 9.2.2 China Neuromyelitis Optica Therapy Market Size by Type (2027-2032)
  5. 9.2.3 China Neuromyelitis Optica Therapy Market Share by Type (2021-2032)
  6. 9.3 China Neuromyelitis Optica Therapy Market Size by Application
  7. 9.3.1 China Neuromyelitis Optica Therapy Market Size by Application (2021-2026)
  8. 9.3.2 China Neuromyelitis Optica Therapy Market Size by Application (2027-2032)
  9. 9.3.3 China Neuromyelitis Optica Therapy Market Share by Application (2021-2032)
10 Asia (Excluding China)
  1. 10.1 Asia Neuromyelitis Optica Therapy Market Size (2021-2032)
  2. 10.2 Asia Neuromyelitis Optica Therapy Market Size by Type
  3. 10.2.1 Asia Neuromyelitis Optica Therapy Market Size by Type (2021-2026)
  4. 10.2.2 Asia Neuromyelitis Optica Therapy Market Size by Type (2027-2032)
  5. 10.2.3 Asia Neuromyelitis Optica Therapy Market Share by Type (2021-2032)
  6. 10.3 Asia Neuromyelitis Optica Therapy Market Size by Application
  7. 10.3.1 Asia Neuromyelitis Optica Therapy Market Size by Application (2021-2026)
  8. 10.3.2 Asia Neuromyelitis Optica Therapy Market Size by Application (2027-2032)
  9. 10.3.3 Asia Neuromyelitis Optica Therapy Market Share by Application (2021-2032)
  10. 10.4 Asia Neuromyelitis Optica Therapy Market Size by Country
  11. 10.4.1 Asia Neuromyelitis Optica Therapy Market Size by Country (2021 VS 2025 VS 2032)
  12. 10.4.2 Asia Neuromyelitis Optica Therapy Market Size by Country (2021-2026)
  13. 10.4.3 Asia Neuromyelitis Optica Therapy Market Size by Country (2027-2032)
  14. 10.4.4 Asia Neuromyelitis Optica Therapy Market Share by Country (2021-2032)
  15. 10.4.5 Japan
  16. 10.4.6 South Korea
  17. 10.4.7 Taiwan
  18. 10.4.8 Southeast Asia
  19. 10.4.9 India
  20. 10.4.10 Australia
11 South America, Middle East & Africa
  1. 11.1 South America, Middle East & Africa Neuromyelitis Optica Therapy Market Size (2021-2032)
  2. 11.2 South America, Middle East & Africa Neuromyelitis Optica Therapy Market Size by Type
  3. 11.2.1 South America, Middle East & Africa Neuromyelitis Optica Therapy Market Size by Type (2021-2026)
  4. 11.2.2 South America, Middle East & Africa Neuromyelitis Optica Therapy Market Size by Type (2027-2032)
  5. 11.2.3 South America, Middle East & Africa Neuromyelitis Optica Therapy Market Share by Type (2021-2032)
  6. 11.3 South America, Middle East & Africa Neuromyelitis Optica Therapy Market Size by Application
  7. 11.3.1 South America, Middle East & Africa Neuromyelitis Optica Therapy Market Size by Application (2021-2026)
  8. 11.3.2 South America, Middle East & Africa Neuromyelitis Optica Therapy Market Size by Application (2027-2032)
  9. 11.3.3 South America, Middle East & Africa Neuromyelitis Optica Therapy Market Share by Application (2021-2032)
  10. 11.4 South America, Middle East & Africa Neuromyelitis Optica Therapy Market Size by Country
  11. 11.4.1 South America, Middle East & Africa Neuromyelitis Optica Therapy Market Size by Country (2021 VS 2025 VS 2032)
  12. 11.4.2 South America, Middle East & Africa Neuromyelitis Optica Therapy Market Size by Country (2021-2026)
  13. 11.4.3 South America, Middle East & Africa Neuromyelitis Optica Therapy Market Size by Country (2027-2032)
  14. 11.4.4 South America, Middle East & Africa Neuromyelitis Optica Therapy Market Share by Country (2021-2032)
  15. 11.4.5 Brazil
  16. 11.4.6 South Africa
  17. 11.4.7 Saudi Arabia
  18. 11.4.8 Turkey
  19. 11.4.9 Argentina
  20. 11.4.9 UAE
  21. 11.4.9 Egypt
  22. 11.4.9 Chile
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources
    8. 13.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst